Advanced search
Start date
Betweenand

Bioactive compounds of Brazilian red propolis on periodontal disease

Grant number: 19/19691-0
Support type:Regular Research Grants
Duration: October 01, 2020 - September 30, 2022
Field of knowledge:Health Sciences - Dentistry - Social and Preventive Dentistry
Principal Investigator:Bruno Bueno Silva
Grantee:Bruno Bueno Silva
Home Institution: Universidade Universus Veritas Guarulhos (Univeritas UNG). Guarulhos , SP, Brazil
Assoc. researchers:Daniele Ribeiro de Araujo ; Magda Feres Figueiredo ; Poliana Mendes Duarte

Abstract

Several diseases are characterized by an exacerbated inflammatory response, standing out periodontitis, that presents high global prevalence. In this way, the search for new immunomodulatory molecules is intense in the literature and the natural products stand out in this area. Among these molecules, neovestitol and vestitol presented anti-inflammatory and antimicrobial properties in vitro, however, there are no reports in the literature about treatment of periodontitis through in vivo models using these compounds. Thus, it has been hypothesized that neovestitol and vestitol have potential as an adjuvant in the treatment of periodontitis. Recently, combination of neovestitol/vestitol (CNV) presented anti-caries and was effective on atherosclerosis treatment through different in vivo models. In addition, it has recently been demonstrated that despite the numerous in vitro studies with natural products, few studies in the dental area have created the conditions for future clinical studies with natural products. Therefore, the objective of the present project is to evaluate the effects of CNV on periodontitis (in different formulations) elucidating its mechanisms of action through the following methodologies: 1- subgingival biofilm related to periodontitis; 2-in vivo models of periodontitis with posterior ELISA and PCR to elucidate the CNV mechanisms. With this proposal, it is expected to demonstrate the pharmacological activity of the compounds through the in vitro and in vivo models, and thus create subsidies for a future clinical study besides obtaining a patent(s) of use of the compound(s). (AU)